BRENDA CARNEY: Open Payments
NPI 1639333230 · NEW HARTFORD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,108 in 74 payments from 17 companies in 2025. Trend: 2023 $1,547 · 2024 $1,690 · 2025 $2,108
Food & beverage: $2,108
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $407 |
| Novo Nordisk Inc | 9 | $250 |
| AstraZeneca Pharmaceuticals LP | 13 | $249 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $230 |
| Lilly USA, LLC | 6 | $217 |
| Janssen Pharmaceuticals, Inc | 2 | $151 |
| Gilead Sciences, Inc. | 4 | $151 |
| Astellas Pharma US Inc | 5 | $98 |
| GlaxoSmithKline, LLC. | 4 | $88 |
| ABBVIE INC. | 4 | $79 |
Products named: CAPLYTA, XIFAXAN, Ozempic, SPRAVATO, ZEPBOUND, AIRSUPRA, Yeztugo, Veozah.
Industry payments across NY — which companies pay providers there.
